The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer
Toi M, Ohashi Y, Seow A, Moriya T, Tse G, Sasano H, Park BW, Chow LW, Laudico AV, Yip CH, Ueno E, Ishiguro H, Bando H. Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i13-18...[10-12-31]
Epigenetic change in E-cadherin and COX-2 to predict chronic periodontitis Loo WT, Jin L, Cheung MN, Wang M, Chow LW. J Trans Med. 2010; Nov 4;8:110 ...[10-11-4]
Curcumin potentiates the pro-apoptotic effects of sulindac sulfone in colorectal cancer Giladi N , Kazanov D, Shpitz B, Aroch I, Kraus S and Arber N. Expert Opin Investig Drugs. Apr 2010;19 Suppl 1: S117-124...[10-4-30]
Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab Longo R , D'Andrea M, Sarmiento R and Gasparini G. Expert Opin Investig Drugs. Apr 2010;19 Suppl 1: S41-50...[10-4-30]
Combination of radiological and biochemical methods to assess bone mineral density of mandible in fully edentulous patients after chemotherapy: a 5-year prospective study Loo WTY , Jin LJ, Cheung MNB, Chow LWC, Wang M. Expert Opin Investig Drugs. Apr 2010;19 Suppl 1: S109-S115...[10-4-30]
Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer patients Loo WTY , Jin LJ, Chow LWC, Cheung MNB, Wang M. Expert Opin Investig Drugs. 2010;19 Suppl 1: S91-100...[10-4-30]
Evolution of endocrine adjuvant therapy for early breast cancer Per Eystein Lønning. Expert Opin Investig Drugs. 2010;19 Suppl 1: S19-30...[10-4-30]
Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer Chow LWC. Expert Opin Investig Drugs. 2010;19 Suppl 1: S13-S17....[10-4-30]
Combat against cancer with science and medicine Chow LWC and Toi M. Expert Opin Investig Drugs. 2010;19 Suppl 1: S3-4....[10-4-30]
Evaluation of the psychological and biological changes of patients diagnosed with benign and malignant breast tumor Bai LJ, Liu Q, Wang M, Loo WT, Cheng RW, Chow LW, Cheung MN, Wei KY, Yip AY, Ng EL. Int J Biol Markers. 2012 Nov 23:0. doi: 10.5301/JBM.2012.9936 ...[13-1-9]
Correlation of epigenetic change and identification of risk factors for oral submucous fibrosis Xu C, Zhao J, Loo WT, Hao L, Wang M, Cheung MN, Dou Y, Yip AY, Ng EL, Chow LW, Liu Q. Int J Biol Markers. 2012 Nov 23:0. doi: 10.5301/JBM.2012.9937 ...[13-1-9]
The clinical trials of the Organisation for Oncology and Translational Research (OOTR) Chow LW, Toi M. Int J Biol Markers. 2012 Dec 14:0. doi: 10.5301/JBM.2012.10371 ...[13-1-9]
Prevention of oncological diseases: primary and secondary prevention Chow LW, Yip AY, Ng EL. Int J Biol Markers. 2012 Dec 14:0. doi: 10.5301/JBM.2012.10370 ...[13-1-9]
Methods of early detection – Would clinical breast examination and breast ultrasonography a good alternative to mammography? Adrian Y.S. Yip, W.P. Chu, Louis W.C. Chow, Wings T.Y. Loo, Eleanor Y.Y. Ong, Wincy Chan. Chin J Breast Dis (Electronic Edition), December 2011, Vol.5, No.6, Pages 646-659...[11-12-31]
Selected Special Lectures of OOTR 7th Annual Conference, 2011 This page is supported by an educational grant from GSK...[11-12-14]
Year in review in Asia - The major Asian trials published in 2011 on Breast Cancer Louis W.C. Chow, Adrian Y.S. Yip, Wai-pui Chu, Eleanor Y.Y. Ong. The Journal of Japan Society of Clinical Oncology, Volume 46, Number 3, 13 Sep 2011, Pages 1176-1181...[11-10-27]
Translational research to realize the full potential of novel agents - an opportunity for vinflunine? Yip AYS, Ong EYY, Chow LWC. Expert Opinion on Drug Safety. 2011 Sep 30 online...[11-9-30]
乳腺癌個體化新輔助治療及輔助手段的套用 周 永昌,魯慶榮,葉潤燊. 中國臨床腫瘤學進展2011 (The 14th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) Educational Book, Sep 2011, Article 37)...[11-9-19]
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow LWC, Yip AYS, Glück S. Eur J Cancer. 2011 Jul 7...[11-7-7]
Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: Sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial Louis W.C. Chow, Adrian Y.S. Yip, W.P. Chu, Wings T.Y. Loo, and Masakazu Toi. The Journal of Steroid Biochemistry and Molecular Biology, Volume 125, Issues 1-2, May 2011, Pages 112-119...[11-5-1]
Application of biomarkers in sentinel lymph node biopsy for the management of breast cancer Qing Liu,Wings Tjing Yung Loo,Adrian Yun San Yip,Louis Wing Cheong Chow,Elizabeth Lam Yan Ng,Mary Ngan Bing Cheung. Chin J Breast Dis( Electronic Edition),December 2012,Vol. 6,No. 6...[12-12-31]
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T. Breast Cancer Res Treat. 2012 Nov 11 ...[12-11-16]
具抗藥性乳腺癌病人的組合性用藥治療方案及其療效和監察的探討 Louis W.C. CHOW, Adrian Y.S. YIP, Qing LIU, Wings T.Y. LOO. The 15th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) Educational Book中國臨床腫瘤學進展2012, pages 240-242 ...[12-9-20]
LMTK3 is implicated in endocrine resistance via multiple signaling pathways Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, Miki Y, Chow LW, Coombes RC, Sasano H, Shaw JA, Giamas G. Oncogene. 2012 Aug 6. doi: 10.1038/onc.2012.343. ...[12-8-6]
New therapies in HER2-positive breast cancer: A major step towards a cure of the disease? Awada A, Bozovic-Spasojevic I, Chow L. Cancer Treat Rev. 2012Aug; 38(5): 494-504...[12-8-1]
Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique Takada M, Sugimoto M, Ohno S, Kuroi S, Sato N, Bando H, Masuda N, Iwata H, Kondo M, Ssano H, Chow LW, Inamoto T, Naito Y, Tomita M, Toi M. Breast Cancer Res Treat. Jun 2012...[12-6-12]
Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1 Yukiko Shibahara,Yasuhiro Miki,Yoshiaki Onodera,Shuko Hata,Monica SM Chan,Christopher CP Yiu,Tjing Y Loo,Yasuhiro Nakamura,Jun-ichi Akahira,Takanori Ishida,Keiko Abe,Hisashi Hirakawa,Louis WC Chow,Takashi Suzuki,Noriaki Ouchi,Hironobu Sasano. The Journal of Pathology, 30 Apr 2012...[12-4-30]
Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis ZhiYu Wang, Wings TY Loo, Neng Wang, Louis WC Chow, Dongmei Wang, Feng Han, Xiao Zheng, Jian-Ping Chen. Expert Opinion on Therapeutic Targets, March 2012, Vol. 16, No. S1, Pages S79-S89...[12-3-30]
Understanding Intratumor Heterogeneity Louis Wing-cheong Chow. The 16th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) Educational Book中國臨床腫瘤學進展2013, pages 505-508...[13-9-26]
Estrogen-receptor antagonist in a premenopausal patient with metastatic breast cancer Chi-Kei Lam, Louis Wing-cheong Chow. Oncology Tribune, May-Jun 2013, P.15-17...[13-6-30]
Status of oral ulcerative mucositis and biomarkers to monitor posttraumatic stress disorder effects in breast cancer patients Loo WT, Liu Q, Yip MC, Wang M, Chow LW, Cheung MN, Yip AY, Ng EL. Int J Biol Markers2013 Jun 28;28(2):e168-73...[13-6-28]
New developments in breast cancer prognosis: molecular predictors of treatment response and survival Foo EM, Boost MV, Wong AS,Loo WT,Chow LW, Chow CY. Int J Biol Markers2013 Jun 28;28(2):e131-40...[13-6-28]
Association of cytokines, high sensitive C-reactive protein, VEGF and beta-defensin-1 gene polymorphisms and their protein expressions with chronic periodontitis in the Chinese population Tian Y, Li JL, Hao L, Yue Y, Wang M, Loo WT, Cheung MN,Chow LW, Liu Q, Yip AY, Ng EL, Chow CY, Chow2 CY. Int J Biol Markers 2013 Apr 23;28(1):e100-e107...[13-4-23]
Application of interleukin-1 genes and proteins to monitor the status of chronic periodontitis Hao L, Li JL, Yue Y, Tian Y, Wang M, Loo WT, Cheung MN,Chow LW, Liu Q, Yip AY, Ng EL. Int J Biol Markers 2013 Apr 23;28(1):e92-9...[13-4-23]
Acceptable cardiac safety profile of neoadjuvant 5-fluorouracil, epirubicin, cyclophosphamide and celecoxib (FEC-C) for breast cancer: a subanalysis of biomarkers for cardiac injury Chow LW, Loo WT, Yip AY, Ng EL. Int J Biol Markers2013 Apr 23;28(1):e92-9...[13-4-23]
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study Chow LW, Tung SY, Ng TY, Im SA, Lee MH, Yip AY, Toi M, Glück S. Expert Opin Investig Drugs. 2013 Mar;22(3):299-307 ...[13-3-1]
Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Antonio C. Wolff, Ann A. Lazar, Igor Bondarenko, August M. Garin, Stephen Brincat, Louis Chow, Yan Sun, Zora Neskovic-Konstantinovic, Rodrigo C. Guimaraes, Pierre Fumoleau, Arlene Chan, Soulef Hachemi, Andrew Strahs, Maria Cincotta, Anna Berkenblit, Mizue Krygowski, Lih Lisa Kang, Laurence Moore, Daniel F. Hayes. J Clin Oncol. 2013 Jan 10;31(2):195-202. doi: 10.1200/JCO.2011.38.3331 ...[13-1-13]
Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients - an immunohistochemical study of cd8+ and foxp3+ using double immunostaining with correlation to the pat Chan MS, Wang L, Felizola SJ, Ueno T, Toi M, Loo W, Chow LW, Suzuki T, Sasano H. Int J Biol Markers. 2012 Dec 19:0. doi: 10.5301/JBM.2012.10439 ...[13-1-10]
Evaluation of the psychological and biological changes of patients diagnosed with benign and malignant breast tumor Bai LJ, Liu Q, Wang M, Loo WT, Cheng RW, Chow LW, Cheung MN, Wei KY, Yip AY, Ng EL. Int J Biol Markers. 2012 Nov 23:0. doi: 10.5301/JBM.2012.9936 ...[13-1-9]
Correlation of epigenetic change and identification of risk factors for oral submucous fibrosis Xu C, Zhao J, Loo WT, Hao L, Wang M, Cheung MN, Dou Y, Yip AY, Ng EL, Chow LW, Liu Q. Int J Biol Markers. 2012 Nov 23:0. doi: 10.5301/JBM.2012.9937 ...[13-1-9]
The clinical trials of the Organisation for Oncology and Translational Research (OOTR) Chow LW, Toi M. Int J Biol Markers. 2012 Dec 14:0. doi: 10.5301/JBM.2012.10371 ...[13-1-9]
Prevention of oncological diseases: primary and secondary prevention Chow LW, Yip AY, Ng EL. Int J Biol Markers. 2012 Dec 14:0. doi: 10.5301/JBM.2012.10370 ...[13-1-9]
